Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Receives Approval for Phase 2/3 COVID-19 Study in Russia
Clinical Trial Application approved in Russia for the Phase 2/3 study with opaganib in severe COVID-19 patients following recent approval in the UK and similar submission in Italy -- The Phase 2/3 study aims to enroll 270 subjects in up to 40 clinical sites; enrollment planned to be initiated later ...
View HTML
Toggle Summary RedHill Biopharma to Present at the Sachs Novel Coronavirus Investment Forum
TEL-AVIV, Israel and RALEIGH, N.C. , July 01, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Gilead Raday , RedHill's Chief Operating Officer, will present the Company’s ongoing Phase 2/3 ...
View HTML
Toggle Summary RedHill Biopharma Receives Approval for COVID-19 Phase 2/3 Study with Opaganib in the UK
The Phase 2/3 multi-center, randomized, double-blind, parallel-arm, placebo-controlled study with opaganib aims to enroll 270 severe COVID-19 patients in up to 40 clinical sites across the UK , Italy , Russia and additional countries  -- In parallel, a U.S. ...
View HTML
Toggle Summary Publication of Data from Severe COVID-19 Patients Shows Substantial Benefit to Patients Treated with RedHill’s Opaganib Compared to Matched Case-Control Group
Analysis of treatment outcomes in five severe COVID-19 patients showed substantial benefit to patients treated with opaganib under compassionate use in both clinical outcomes and inflammatory markers as compared to a matched case-control group from the same hospital -- All patients in the ...
View HTML
Toggle Summary RedHill Biopharma Expands Opaganib COVID-19 Phase 2/3 Study with Clinical Trial Applications in Italy and UK
The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 clinical study with opaganib in 270 severe COVID-19 patients is planned to be conducted in up to 40 clinical sites across Russia , Italy , the UK and additional countries -- In parallel, a clinical study of ...
View HTML
Toggle Summary RedHill Biopharma to Present at Virtual Life Sciences Investor Forum on June 25
TEL-AVIV, Israel and RALEIGH, N.C. , June 18, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Guy Goldberg , RedHill's Chief Business Officer, will present a corporate overview at the Virtual ...
View HTML
Toggle Summary RedHill Biopharma Submits COVID-19 Clinical Trial Application for Phase 2/3 Study with Opaganib
The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 clinical study of opaganib for severe COVID-19 patients is planned to be conducted in Russia and additional European and other countries -- In parallel, a Phase 2a clinical study of opaganib for severe COVID-19 ...
View HTML
Toggle Summary RedHill Biopharma to Provide Update on its COVID-19 and other Development Programs at MedInvest Virtual Infectious Diseases and Immunology Conference
TEL-AVIV, Israel and RALEIGH, N.C. , June 08, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Gilead Raday , RedHill’s Chief Operating Officer, will present the Company’s development ...
View HTML
Toggle Summary RedHill Biopharma to Present at BIO Digital
TEL-AVIV, Israel and RALEIGH, N.C. , June 01, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Adi Frish , RedHill’s Senior Vice President Business Development and Licensing, will present a ...
View HTML
Toggle Summary RedHill Biopharma to Present at Jefferies Virtual Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C. , May 28, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Dror Ben-Asher , RedHill’s Chief Executive Officer, will present a corporate overview at the ...
View HTML